such, their gain or loss of function might not involve mutations, are not sufficient for tumorigenesis, and show tissue-specific features. Upregulation of the majority of homeobox genes, for example the prototypical HOX family, are associated with oncogenesis. Two exceptions are the NKX3.1 and CDX2 homeobox genes, in which loss of function have been, respectively, associated with prostate and colorectal tumorigenesis (Abate-Shen, 2002) .
CDX2 is a Drosophila caudal-related homeobox transcription factor that is important for the establishment and maintenance of intestinal epithelial cells (James et al., 1994) . CDX2 expression is confined to the intestinal epithelium and has been shown to regulate intestinal gene transcription, differentiation, and proliferation (Suh and Traber, 1996; Beck, 2002; Guo et al., 2004b) .
Mice that are heterozygous-null for Cdx2 develop colonic hamartomas after the remaining Cdx2 allele is lost (Chawengsaksophak et al., 1997; Tamai et al., 1999) . These heterozygous-null Cdx2 mice are also more sensitive to azoxymethan-induced colonic adenocarcinomas (Bonhomme et al., 2003) . Furthermore, mice that are compound heterozygotes for Cdx2 and the tumor suppressor Adenomatous Polyposis Coli (Apc) develop more adenomatous polyps in the colon than their heterozygous Apc littermates (Aoki et al., 2003) . These studies have implied that CDX2 is a putative tumor suppressor.
CDX2 expression is deregulated in human colorectal cancer. CDX2 expression was initially reported to be reduced in colonic adenomas and adenocarcinomas, with an inverse relationship between CDX2 and advanced stages of cancers (Ee et al., 1995; Mallo et al., 1997) . More recent data have contradicted these earlier findings. Using large tissue microarrays, CDX2 expression was shown to be strongly present in 90% of colon cancers (Moskaluk et al., 2003) .
A second recent large study demonstrated strong CDX2 staining in up to 97.9% of colonic adenomas and 85.7% of colonic adenocarcinomas (Kaimaktchiev et al., 2004) . Altogether, it appears that CDX2 is indeed expressed in all stages of colorectal cancer; however, its biological function in this context remains unclear.
CDX2 is rarely mutated in colon cancer. While a few tumors with high microsatellite instability harbor truncating mutations of CDX2 in areas of repetitive DNA sequence, it remains unclear whether these are functional or 'bystander' mutations as a result of the DNA mutator phenotype (Wicking et al., 1998; Yagi et al., 1999; Woodford-Richens et al., 2001) . Furthermore, the paucity of CDX2 mutations in colon cancer has led to suggestions that CDX2 may play only a minor role in colon carcinogenesis (Yagi et al., 1999) . As such, a recent study did not identify an association between CDX2 polymorphisms or RNA expression to colon cancer susceptibility or tumor stage (Rozek et al., 2005) . Thus, the epidemiology studies have not supported that CDX2 is a tumor suppressor.
In human colon cancer cell lines that express low levels of CDX2, in vitro overexpression of CDX2 reduced proliferation, increased compaction and differentiation, and significantly altered the transcription of genes regulating these processes (Guo et al., 2004b) . Thus far, the functional contributions of CDX2 to tumorigenesis have been assessed in HT29 colon cancer cells (Mallo et al., 1998) . While overexpression of CDX2 alone reduced in vitro HT29 cell proliferation, it did not alter in vivo xenograft growth. Potential explanations for the lack of an effect with CDX2 overexpression in HT29 cell tumorigenicity was the lack of CDX1 (Mallo et al., 1998) , or the presence of a dominant repression mechanism in CDX2 silencing (Hinoi et al., 2003) . In another low-CDX2-expressing colorectal cancer cell line (RKO), we found that wild-type CDX2 positively transactivated the promoter of the putative tumor suppressor KLF4, but truncated CDX2 negatively transactivated the KLF4 promoter (Dang et al., 2001a) . This suggested that mutated CDX2 might have an oncogenic effect through a dominant-negative mechanism. However, RKO cells harbor one mutated allele of CDX2 and decreased transactivation of the remaining allele; hence the CDX2 transcription machinery may be compromised (da Costa et al., 1999) . Thus, a challenge in studying the functional contributions of CDX2 to tumorigenicity in colon cancer cell lines with low-CDX2 expression is the compromised transcription machinery; either due to the presence of repressor mechanisms, the absence of cooperating partners, or the diminished capacity for autologous transactivation. In addition, efforts to inhibit CDX2 expression in colon cancer cells lines using RNA interference have not yet yielded optimal results (Hinoi et al., 2005) .
In an effort to better understand the functional contributions of CDX2 to colorectal cancer, we genetically disrupted CDX2 in the human colon cancer cell lines LOVO and SW48 using targeted homologous recombination. Both cell lines express CDX2, with LOVO harboring two wild-type alleles, and SW48 harboring one wild-type and one mutated allele of CDX2. We reasoned that targeted disruption would result in specific, complete, and permanent inactivation of CDX2 in colon cancer cells that have intact CDX2 transcription machinery. Comparisons of cell lines that are essentially identical except for the presence or absence of CDX2 would allow us to directly determine how CDX2 functions in colon cancer.
CDX2 expression, sequence analysis, and disruption in colon cancer cell lines: The expression of CDX2 in colorectal cancer cell lines was examined by Western blot analyses (Figure 1a) . Consistent with the literature, CDX2 was highly expressed in LS174T, SW480, SW48, and LOVO cells; and nearly absent in HT29, HCT116, and RKO cells (Hinoi et al., 2003) . The CDX2 gene was sequenced, with particular attention to the G(7) repeat site in exon 3 of the genomic sequence, which corresponded to nucleotide 1083 of CDX2 cDNA. This G(7) tract was reported to be frequently mutated by a deletion of one G, which was predicted to result in early termination and truncation of the final five amino acids (Yagi et al., 1999; Hinoi et al., 2003) . LOVO cells were found to harbor two wild-type alleles of CDX2, including the G(7) tract, as seen in both genomic and cDNA sequences (Figure 1b ). SW48 cells harbored one wild-type and one mutated allele of CDX2. The mutation is a deletion of a G in the G7 sequence, as shown by the superimposed sequence starting after G6 in the genomic DNA, and the presence of two different populations of cDNA (Figure 1b) . Consistent with published reports (da Costa et al., 1999; Hinoi et al., 2003) , CDX2 is wild type in LS174T and HT29 cells, and mutated in one allele of HCT116 and RKO cells.
The CDX2 locus in LOVO and SW48 cells was targeted for disruption ( Figure 1c ). Disruption was confirmed by locus-specific PCR and Western blot analyses (Figure 1d and e). Four clones of LOVO homozygous-null CDX2 cells were isolated and will be referred to as LOVO CDX2À/À cells. The rate of successful homologous targeting was estimated to be B1%. To control for clonal variation with passage, parental cells were passed in parallel with knockout cells and four independent clones of CDX2À/À cells were selected for further analyses.
In SW48 cells, we screened 2000 heterozygous knockout clones and identified 67 with locus-specific targeting. Of these clones, 66 were specific retargeting to the already disrupted CDX2 allele. Only one clone was homozygous for CDX2 disruption. This one clone was not viable beyond B5 cell divisions upon subsequent expansion. These findings in SW48 cells are highly consistent with cell lethality after homozygous disruption of CDX2.
Loss of CDX2 enhances cell proliferation under anchorage-dependent conditions: The term anchorage dependence characterizes cells that require a solid substratum for growth, for example the solid glass or plastic surface of a culture dish. As expected, disruption of CDX2-enhanced anchorage-dependent cell proliferation (Figure 2a) . LOVO CDX2À/À cells had a B10-35% increase in colony formation compared to LOVO cells, which was not statistically significant ( Figure 2a ). In addition, LOVO CDX2À/À cells were observed to form colonies that were less compact and multicellular when compared to LOVO cells (Figure 2b ). Finally, disruption of CDX2 resulted in a decrease in expression of the colonocyte differentiation markers carbonic anhydrase, NHE2, and MUC2; decreased expression of the cyclindependent kinase inhibitor p21 WAFÀ1/CIPÀ1 ; and increased expression of cyclin D1 (Figure 2c ). Our findings are consistent with published reports, in which overexpression of CDX2 in anchorage-dependent cell cultures led to: (1) decreased cell proliferation and expression of cyclin D1; and (2) increased cell aggregation, expression of p21, and genes involved in colonocyte differentiation (Mallo et al., 1998; Hinoi et al., 2003; Guo et al., 2004b; Keller et al., 2004) . Ladder CDX2 (Drewinko et al., 1976) . LOVO cells harbor an endogenous mutation in one allele of APC and KRas, wild-type b-catenin and wild-type p53 (Koo et al., 1996; Rowan et al., 2000; Russo et al., 2002) . SW48 cells were derived from an 83-year-old female with poorly differentiated Duke's Stage C colorectal cancer (Leibovitz et al., 1976) . SW48 cells harbor an endogenous mutation in b-catenin, wild-type APC, and wild-type p53 (Rowan et al., 2000; Hwang et al., 2001; Russo et al., 2002) . Both cell lines are near diploid (Rowan et al., 2000) . Three primer sets were used to amplify the three CDX2 exons and exon-intron boundaries from genomic DNA: exon 1 primers: 5 0 -CTCTGCAGCCTAGTGGGAAG-3 0 (forward) and 5 0 -TCACTCCCAGGCT CAGTAGG-3 0 (reverse), exon 2 primers: 5 0 -GGGTGGTGGAGGAAGAGAA-3 0 (forward) and 5 0 -CCAAAGACGAATGCTTG CAT-3 0 (reverse), and exon 3 primers: 5 0 -ATGCCCGAGGAAAGCTTCTA-3 0 (forward) and 5 0 -TGCTCTGGGGTAAAATGAGG-3 0 (reverse). In addition, total RNA was extracted from cells, reverse transcribed, and the B1 kb coding region of CDX2 amplified to generate cDNA using the primers 5 0 -GCCACCATGTACGTGAGCTA-3 0 (forward) and 5 0 -CTCAGCCTGGAATTGCTCTG-3 0 (reverse). All products were sequenced by the University of Michigan Sequencing Core Facility. Sequences were aligned using the BL2SEQ program from the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov). (c) Targeted disruption of CDX2. The endogenous locus, adeno-associated virus (AAV) knockout construct, and resulting targeted locus are shown in diagram form. Numbered boxes represent exons. ITR ¼ inverted terminal repeats; HA ¼ homology arm; P ¼ SV40 promoter; Neo ¼ neomycinresistance gene; pA ¼ polyA tail; triangles ¼ loxP sites. Primers P1 and P2, which amplify exon 1, are shown. The strategy is as previously described (Chan et al., 2002; Cummins et al., 2004a, b; Kohli et al., 2004; Dang et al., 2005) . Exon 1 of CDX2 was targeted for disruption with an AAV cassette containing the Neomycin resistance gene (Neo) under the constitutive control of an SV40 promoter flanked by left and right homology arms approximately 1 kb in length. Successful disruption resulted in a 250 bp deletion and translation stop codons in all three reading frames. Cells exhibiting neomycin resistances were screened with locus-specific PCR using primers specific for exon 1 (Figure 1d ). Once the first allele was successfully targeted, the Neo was excised using Cre recombinase (Microbix Biosystems Inc., Toronto, Canada). The same targeting vector was then used to target the second allele. (d) Genomic locusspecific PCR using primers P1 and P2 to confirm homologous integration of the targeting vector. Lane 1: the endogenous locus contains a B350 bp fragment. Lane 2: after successful targeting of the first allele and treatment with Cre recombinase, the amplification product is a smaller, B250 bp fragment. With successful targeting of the second allele, the amplification product is a B1650 bp fragment encompassing the Neo gene. (e) Confirmation of loss of CDX2 protein expression. Western blot for CDX2 expression in LOVO cells (lane 1) and LOVO CDX2À/À clones 1-4 (lanes 2-5).
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Loss of CDX2 decreases cell proliferation under anchorage-independent conditions: Anchorage-independent growth is an important hallmark of cell transformation and better correlates with in vivo oncogenic potential (Evan and Vousden, 2001; Hahn and Weinberg, 2002) . Most normal cells derived from solid animal tissues are anchorage-dependent and show a finite life span. Loss of anchorage-dependence or acquisition of anchorage-independence is usually a sign of cell transformation. As we were seeking to determine the effects of CDX2 in colon cancer cells, which are transformed, we examined the effects of CDX2 disruption on anchorage-independent growth. To our surprise, we found that disruption of CDX2 markedly reduced anchorage-independent growth in soft agar (Figure 2d (Figure 2e , second graph). Thus, LOVO CDX2À/À clones 1 and 4 were selected for subsequent studies because they represented this variability in colony numbers and sizes. Ultimately however, loss of CDX2 resulted in significant decreases in anchorage-independent colony formation ( Figure 2e , third graph). These results, combined with our inability to isolate homozygous-null CDX2 clones of SW48 cells, , and cyclin D1. Relative expression was calculated using the formula, ratio ¼ 2 -[CPexperimental -CPGAPDH] (Pfaffl, 2001) . CP ¼ crossing point at which fluorescence rises appreciably above the background fluorescence. Each experiment was performed in triplicate and repeated twice. Two-tailed Student's t-test was used to determine whether the differences between LOVO and both clones of LOVO CDX2À/À were statistical significant, *Po0.01. (d) Anchorageindependent colony formation. Phase-contrast photomicrograph of LOVO and LOVO CDX2À/À clones in soft agar, at Â 20 (low power field). Bars ¼ 1.0 mm. For anchorage-independent growth assays, 2.0 Â 10 4 cells per well were suspended in 0.33% agar and plated on six-well plates layered with 0.5% agar. Cells were allowed to grow for 2 weeks, spherical colonies photographed at Â 20, and quantitated using Image Pro Plus software. (e) Anchorage-independent colony formation on soft-agar plates. The bars in the first graph represent the average number of colonies formed by the different cell lines. The bars in the second graph represent the mean area of the colonies formed by the different cell lines. The bars in the third graph represent the percent of the agar plate covered by cell colonies (colonies: plate density) in the different cell lines. N ¼ 10 low power fields for each bar, *Po0.05, Student's t-test comparing LOVO CDX2À/À to LOVO cells.
suggested that CDX2 might have tumorigenic potential under anchorage-independent conditions. Disruption of CDX2 induces anchorage-independent growth arrest and anoikis: To begin to determine the mechanisms by which CDX2 promoted anchorageindependent growth, LOVO and LOVO CDX2À/À cells were studied in culture using the over-agar method. Under these conditions, the cells essentially grew in suspension (Figure 3a) . LOVO CDX2À/À cells grown overagar had significantly slower rates of proliferation than LOVO cells (Figure 3b ). Cell cycle analyses revealed G1-to S-phase arrest in LOVO CDX2À/À cells compared to LOVO cells: there was a 15% increase in cells in the G1-phase and almost 10% decrease in cells in the Sphase (Figure 3c ). This G1 to S arrest in LOVO CDX2À/À was aptly associated with increased expression of p21 WAFÀ1/CIPÀ1 (Figure 3d ). It is interesting that under anchorage-dependent conditions, CDX2 transactivated the p21 WAFÀ1/CIPÀ1 promoter (Bai et al., 2003) , and modestly upregulated p21
WAFÀ1/CIPÀ1 expression ( Figure 2c ). Yet, under anchorage-independent conditions, loss of CDX2 was associated with increased p21 WAFÀ1/CIPÀ1 . The mechanisms for this paradox are unclear, but the observation underscores the contrasts in how CDX2 functions under anchorage-dependent and -independent conditions. It is perplexing that increased expression of cyclin D1 was preserved in LOVO CDX2À/À cells under anchorage-independent conditions (Figure 3d ). These findings reaffirmed our observations under anchorage-dependent conditions ( Figure 2c) ; as well as previous reports that CDX2 negatively regulates cyclin D1 (Guo et al., 2004a) . However, it is unlikely that the increased expression of the growth promoter cyclin D1 contributed to the observed decrease in anchorage-independent growth in LOVO CDX2À/À cells. We next examined activation of ERK, a known mediator of anchorage-independent growth progression (Sebolt- Leopold and Herrera, 2004) . We found that LOVO CDX2À/À cells exhibited decreased phosphorylation of ERK (Figure 3e ). Thus, CDX2 mediates anchorage-independent cell growth, likely through an as yet undefined mechanism by which ERK is phosphorylated and p21 expression is downregulated.
CDX1 is a homeodomain transcription factor with high structural homology to CDX2, overlapping patterns of expression, and complementary roles in the adult intestine (Freund et al., 1998; Guo et al., 2004b) . We found that loss of CDX2 was associated with increased CDX1 expression (Figure 3d) . The interplay between CDX2 and CDX1 are likely complex. Nevertheless, CDX1 has been reported to inhibit colon cancer cell proliferation (Lynch et al., 2000 (Lynch et al., , 2003 Guo et al., 2004a) . Thus, we can carefully speculate that induction of CDX1 might contribute to the anchorageindependent growth arrest that is associated with loss of CDX2.
Anoikis is programmed cell death caused by loss of adhesion to a substrate (Igney and Krammer, 2002) . Anoikis is a hallmark of untransformed cells, and resistance to anoikis is a hallmark of transformed cells. LOVO CDX2À/À cells grown over-agar exhibited a 10-fold increase in cell death compared to LOVO cells (Figure 3f ). This cell death was in part mediated by caspase-dependent apoptosis, as demonstrated by increased cleavage of the terminal caspase-3 and the nuclear protein PARP in LOVO CDX2À/À cells (Figure 3g  and h ). CDX2 has also been shown to induce the antiapoptotic factor Bcl-2 in lymphoma cells (Heckman et al., 2000) . As such, we found that loss of CDX2 was associated with decreased Bcl-2 expression and increased Bcl-2 phosphorylation (Figure 3 ). Decreased Bcl-2 is associated with apoptosis, while increased Bcl-2 phosphorylation can be tightly associated with mitotic arrest (Ling et al., 1998) . Finally, loss of CDX2 in LOVO CDX2À/À cells was associated with decreased phosphorylation of FAK, a known mediator of resistance to anoikis (McLean et al., 2004) (Figure 3j ). Altogether, these data demonstrate that under anchorage-independent conditions, CDX2 promotes cell survival and resistance to anoikis in LOVO cells.
Disruption of CDX2 inhibits xenograft growth: Collectively, our in vitro findings demonstrated that CDX2 weakly suppressed anchorage-dependent growth; yet at Figure 3 Cell proliferation and apoptosis under anchorage-independent conditions. (a) Phase-contrast photomicrograph of LOVO and LOVO CDX2À/À colonies growing in suspension on over-agar cultures. Bar ¼ 1.0 mm. The over-agar cell culture method enables ready recovery of cells growing in anchorage-independent conditions. Cells were trypsinized, gently dispersed, and plated in complete media over 0.5% agar (Dong and Cmarik, 2002) . For cell recovery, the liquid growth medium and unattached cells were transferred to a conical tube, centrifuged, and the cells recovered. (b) Quantitation of LOVO and LOVO CDX2À/À cell proliferation. N ¼ 12 wells for each point. *Po0.001, Student's t-test comparing LOVO to LOVO CDX2À/À cells. (c) Representative cell cycle analysis. Bars represent the percentage of the cell population in G 0 /G 1 , S, and G 2 /M phases. N ¼ 10 000 cells. For cell cycle analyses, cells were permeated with 70% ice-cold ethanol and stained with 50 mg/ml propidium iodide in PBS containing 0.2% Tween 20 and 2.5 mg/ml RNase. DNA content was measured on a FACSCalibur Cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and data were analysed using Modfit Lt software (Verity Software House, Topsham, ME, USA). (d) Western blot of p21
, cyclin D1, and CDX1. p21 WAFÀ1/ CIPÀ1 is 21 kDa, cyclin D1 is 36 kDa, and CDX1 is 37 kDa. (e) Western blot of phosphorylated and total ERK. Phosphorylated ERK and total ERK consist of ERK1 and ERK2, which are 44 kDa (top band of doublet) and 42 kDa (bottom band of doublet). (f) Apoptosis index. The bars represent the percent of cells with pyknotic nuclei after 4 and 7 days in culture. N ¼ 8 wells for each bar. *Po0.05, Student's t-test comparing LOVO CDX2À/À to LOVO cells. For calculations of apoptosis index, cells were stained with Hoescht 33258 and the number of cells with pyknotic nuclei and intact nuclei counted as previously described (Jacobson and Raff, 1995) . the same time strongly promoted anchorage-independent growth. As in vitro anchorage-independent growth is better correlated with in vivo growth, these data would suggest that CDX2 has tumorigenic potential. To more directly examine the effects of CDX2 on tumors, we determined the effects of CDX2 on in vivo xenograft growth. Tumor cells were implanted into the flanks of athymic nude mice and the ensuing xenografts measured. Loss of CDX2 significantly hindered xenograft growth in both LOVO CDX2À/À clones. After 25 days of growth, LOVO CDX2À/À xenografts attained volumes that were B6-fold smaller than LOVO xenografts (Figure 4a) . Histologically, LOVO xenografts were noted to consist of two distinct compartments of live cells. Towards the central region of the LOVO xenografts were luminal structures lined by columnar epithelial cells, which were consistent with glandular differentiation and adenocarcinoma morphology (Figure 4b ). This inner zone was surrounded by a peripheral zone of solid sheets or nests of undifferentiated carcinoma (Figure 4b ). This histology is consistent with the histology reported in LS174T xenografts implanted orthotopically on the cecum of mice, in which CDX2 was found in the central differentiated region, but not the peripheral undifferentiated region (Brabletz et al., 2004) . However, we noted no significant differences in the gross morphology or relative composition of the differentiated and undifferentiated compartments in LOVO CDX2À/À xenografts. This would suggest that CDX2 expression did not grossly alter the differentiated compartments of xenografts. Altogether, these in vivo xenograft studies support the in vitro results that CDX2 promotes anchorage-independent growth.
In this report, we have directly demonstrated that CDX2 has tumorigenic potential in colon cancer cells, by promoting anchorage-independent growth and resistance to anoikis. To our knowledge, these are the first studies to show that CDX2 has tumorigenic potential in human colon cancer cells. While these findings are novel, they are not surprising in the context of previous studies that have alluded to the positive growth properties of CDX2. Up to 56% of CDX2 heterozygote-null mice neonates were smaller than their wild-type littermates (Chawengsaksophak et al., 1997) . Homozygous-null CDX2 embryos do not implant in vivo due to defective trophoblastic development. Even when the defective trophoblastic development trait was rescued, the embryos did not survive past 11.5 days due to the failure of the allantois to adhere to the chorion, to form a functional placenta (Chawengsaksophak et al., 2004) . Intriguingly, the embryos exhibited decreased Fgf and Wnt growth signals, which suggested that CDX2 may mediate these growth stimulatory pathways (Chawengsaksophak et al., 2004) . In another system of rat intestinal epithelial cells, overexpression of Cdx2 initially inhibited proliferation; but later enhanced postconfluence proliferation (Suh and Traber, 1996) . Finally, ectopic expression of Cdx2 is the transforming event in a mouse model of acute myeloid leukemia (Rawat et al., 2004) . Specifically, Cdx2 expression in bone marrow cells significantly increased anchorage-independent colony formation in methylcellulose, peripheral blood, and the spleen (Rawat et al., 2004) . Combining the results of the above studies and this study, it would appear that CDX2 is essential for anchorage-independent cell growth and survival.
In these human colon cancer cells studied, the role of CDX2 in differentiation may be limited. In LOVO CDX2À/À tumors, the noted decreases in molecular differentiation markers were small, and the differentiated compartments persisted within the xenografts. Thus, the dominant phenotype in this model of CDX2 disruption was lack of anchorage-independent growth rather than lack of glandular differentiation.
That CDX2 has tumorigenic potential adds potential new insights to the literature regarding its expression in human colon cancers. CDX2 may be widely expressed in colon cancer because it promotes cell survival. The inverse relationship between CDX2 expression and tumor differentiation has led to suggestions that CDX2 is a tumor suppressor. However, it remains unclear if less differentiated colon cancers are more tumorigenic. For example, the differentiation states of colon cancers do not alter their therapeutic management. Furthermore, we can speculate that the frequent loss of CDX2 in large-cell minimally differentiated carcinomas of the colon may contribute to their more favorable prognosis (Sugao et al., 1997; Hinoi et al., 2001 ). Bar ¼ 100 mm. The arrowheads point to luminal structures seen in the differentiated inner zone and the asterisk depicts the undifferentiated outer zone of the xenograft. Colored image is available online. Cells were implanted subcutaneously into the flanks of 6-week old female athymic nu/nu mice (Charles River Labs, Wilmington, MA, USA) (Dang et al., 2001b (Dang et al., , 2004 . Tumor sizes in two dimensions were measured with calipers, and volumes were calculated with the formula (L Â W 2 ) Â 0.5, where L is length and W is width. Mice were housed in barrier environments, with food and water provided ad libitum as approved by the University of Michigan Animal Care and Use Committee. Mice were euthanized once overwhelmed by tumor burden as defined by animal care guidelines.
That CDX2 has tumorigenic potential in colon cancer cells contrasts with its role as a putative tumor suppressor in murine models of colonic neoplasms (Chawengsaksophak et al., 1997; Tamai et al., 1999; Aoki et al., 2003; Bonhomme et al., 2003) . We can only speculate on potential explanations for these observed contrasts. First, perhaps CDX2 has different functions depending on cellular context. CDX2 might function differently in transformed colon cancer cells compared to untransformed mouse enterocytes. For example, the lack of LI-cadherin expression in LOVO and SW48 cells might alter CDX2 function in these cell lines (Hinoi et al., 2002) . Alternatively, colonic tumors from heterozygous-null Cdx2/Apc mice exhibited loss of heterozygosity (LOH) at the Apc locus (Aoki et al., 2003) ; whereas there is no LOH at the APC locus in LOVO or SW48 cells (Rowan et al., 2000) . It is possible that LOH of APC, the intestinal gatekeeper, regulates CDX2 function (da Costa et al., 1999) . Second, it is possible that environmental cues modulate CDX2 function. In the present report, loss of CDX2 enhanced growth under anchorage-dependent conditions; yet inhibited growth under anchorage-independent conditions. In the same vein, heterozygous loss of Cdx2 in mice inhibited overall body growth; yet enhanced the propensity for colonic tumors (Chawengsaksophak et al., 1997; Tamai et al., 1999) . Third, the level of CDX2 expression may contribute to its function. Even within the same mouse model, homozygous loss of cdx2 was lethal whereas heterozygous loss of Cdx2 was eventually tumorigenic (Chawengsaksophak et al., 1997; Tamai et al., 1999; Aoki et al., 2003; Bonhomme et al., 2003) .
The molecular mechanisms by which CDX2 mediates anchorage-independent growth and resistance to anoikis are unknown, although its role in adhesion is a logical candidate mechanism (Keller et al., 2004) . The cancer tissue specificities in which CDX2 has oncogenic potential are likely varied. CDX2 appears to contribute to oncogenic potential in a mouse model of leukemia and with this report, two colon cancer cell lines. However, we have observed that CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45 (Dang et al., 2006) . Certainly, further investigations are warranted and ongoing. Nevertheless, these are the first studies to directly demonstrate that CDX2 has tumorigenic potential in human colon cancer cells.
